News from edison pharmaceuticals

Jun 09, 2014, 00:01 ET

FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Leigh Syndrome

 Edison Pharmaceuticals today announced that the FDA has granted Orphan Drug status to vatiquinone for the treatment of Leigh syndrome....

May 21, 2014, 00:01 ET

Edison Pharmaceuticals' EPI-743 Granted Orphan Designation for Leigh Syndrome in Japan

Edison Pharmaceuticals today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Designation to EPI-743 for...

Mar 17, 2014, 00:01 ET

Edison Pharmaceuticals Announces Initiation of EPI-743 Pearson Syndrome Clinical Trial

Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743...

Mar 17, 2014, 00:01 ET

FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia

Edison Pharmaceuticals today announced that the United States Food and Drug Administration granted Fast Track designation to EPI-743, the company's...

Mar 10, 2014, 00:01 ET

Edison Announces Initiation of EPI-743 Phase 2B/3 Leigh Syndrome Clinical Trial With Dainippon Sumitomo Pharma Co. Ltd. in Japan

Edison Pharmaceuticals today announced the initiation of a phase 2B/3 study entitled, "A Phase 2B/3 Open-label Study of EPI-743 in Children with...

Feb 04, 2014, 00:01 ET

FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Friedreich's Ataxia

Edison Pharmaceuticals today announced that the US Food and Drug Administration has granted Orphan Status to vatiquinone for the treatment of...

Jan 31, 2014, 01:30 ET

Edison Pharmaceuticals, Inc. enters into strategic alliance with Dainippon Sumitomo Pharma Co., Ltd.

 Edison Pharmaceuticals today announced that it has entered into a strategic alliance valued up to $4.295 billion with Dainippon Sumitomo...

Nov 04, 2013, 00:01 ET

Edison Pharmaceuticals, FARA, and USF Announce Initiation of EPI-743 Phase 2 Friedreich's Ataxia Clinical Trial in Adults with Point Mutations

Edison Pharmaceuticals, the Friedreich's Ataxia Research Alliance (FARA) and the University of South Florida (USF) today announced the initiation...

Sep 24, 2013, 10:36 ET

Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients

 Edison Pharmaceuticals announced today initiation of a phase 2 clinical trial titled "Therapeutic Trial of EPI-743 in Patients with Disorders...

Mar 28, 2013, 08:55 ET
Feb 19, 2013, 00:01 ET

Edison Pharmaceuticals & Bambino Gesu Children's Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial

 Edison Pharmaceuticals today announced the initiation of a phase 2 clinical trial entitled, "Double-Blind, Placebo-Controlled Clinical Trial...

Jan 07, 2013, 00:01 ET

Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Friedreich's Ataxia Clinical Trial

Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "Safety and Efficacy Study of EPI-743 on Visual Function in...

Nov 26, 2012, 11:20 ET

Edison Pharmaceuticals Closes $20M Series F Financing

Edison Pharmaceuticals, Inc. announced today that it has closed a Series F Preferred Financing, raising $20M. Mitsui & Co. Global Investment,...

Nov 13, 2012, 00:01 ET

Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial

 Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "A Phase 2B Randomized, Placebo-Controlled, Double-Blind...

Sep 13, 2012, 00:01 ET

Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial

Edison Pharmaceuticals today announced positive results of a recently completed phase 2A study entitled, "Prospective Open Label Study of EPI-743...

Sep 12, 2012, 00:01 ET

EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome

 Edison Pharmaceuticals announced today that the Committee for Orphan Medicinal Products (COMP), European Medicines Agency, has granted...

Sep 13, 2011, 11:56 ET

Edison Pharmaceuticals, Inc. Closes Financing

Edison Pharmaceuticals, Inc. announced today that it has closed a Series E Preferred Financing. Capital raised will fund US and European approval...

Jun 10, 2011, 17:38 ET

Edison Pharmaceuticals Announces Results of EPI-A0001 Phase 2A Double Blind Placebo Controlled 28-Day Clinical Trial in the Mitochondrial Disease- Friedreich's Ataxia

Edison Pharmaceuticals, Inc. announced today preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia. While the...

Jun 08, 2011, 22:37 ET

Edison Pharmaceuticals annonce l'octroi de la désignation de medicament orphelin EPI-743 de la FDA

- Cette désignation couvre les maladies en rapport avec un trouble de la chaîne respiratoire de la mitochondrie Edison...

Jun 08, 2011, 18:11 ET

Edison Pharmaceuticals élargit l'accès à EPI-743 pour les maladies mitochondriales

- La FDA autorise l'utilisation d'un nouveau médicament expérimental pour les cas menaçant le pronostic vital Edison...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
ReportBuyer
Investor-Edge